These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26394830)

  • 21. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
    Derangère V; Fumet JD; Boidot R; Bengrine L; Limagne E; Chevriaux A; Vincent J; Ladoire S; Apetoh L; Rébé C; Ghiringhelli F
    Oncotarget; 2016 Feb; 7(8):9309-21. PubMed ID: 26824184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR; Cohn A; Dakhil S; Saleh M; Piperdi B; Cline-Burkhardt M; Tian Y; Go WY
    Clin Colorectal Cancer; 2015 Jun; 14(2):72-80. PubMed ID: 25982297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer.
    Pentheroudakis G; Kotoula V; Kouvatseas G; Charalambous E; Dionysopoulos D; Zagouri F; Koutras A; Papazisis K; Pectasides D; Samantas E; Dimopoulos MA; Papandreou CN; Fountzilas G
    Clin Breast Cancer; 2014 Oct; 14(5):330-8. PubMed ID: 24703319
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
    Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
    J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of survival and prognostic factors in metastatic colorectal cancer patients treated with first-line bevacizumab-based therapy.
    Demircan NC; Dane F; Ozturk MA; Babacan NA; Besiroglu M; Kaya S; Ercelep O; Tanrikulu E; Halil S; Koca S; Alan O; Hasanov R; Yumuk PF
    J BUON; 2019; 24(4):1494-1500. PubMed ID: 31646797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.
    Nasir A; Reising LO; Nedderman DM; Fulford AD; Uhlik MT; Benjamin LE; Schade AE; Holzer TR
    Anticancer Res; 2016 Jun; 36(6):2683-96. PubMed ID: 27272777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
    Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
    PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
    Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
    Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
    Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
    Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A plasma cytokine and angiogenic factor (CAF) analysis for selection of bevacizumab therapy in patients with metastatic colorectal cancer.
    Bai L; Wang F; Zhang DS; Li C; Jin Y; Wang DS; Chen DL; Qiu MZ; Luo HY; Wang ZQ; Li YH; Wang FH; Xu RH
    Sci Rep; 2015 Dec; 5():17717. PubMed ID: 26620439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Sluiter NR; de Cuba EM; Kwakman R; Meijerink WJ; Delis-van Diemen PM; Coupé VM; Beliën JA; Meijer GA; de Hingh IH; te Velde EA
    Clin Exp Metastasis; 2016 Apr; 33(4):297-307. PubMed ID: 26873137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab.
    Marisi G; Scarpi E; Passardi A; Nanni O; Ragazzini A; Valgiusti M; Casadei Gardini A; Neri LM; Frassineti GL; Amadori D; Ulivi P
    Sci Rep; 2017 May; 7(1):1293. PubMed ID: 28465540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen.
    Lereclus E; Tout M; Girault A; Baroukh N; Caulet M; Borg C; Bouché O; Ternant D; Paintaud G; Lecomte T; Raoul W
    BMC Cancer; 2017 Mar; 17(1):220. PubMed ID: 28347290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
    Stein A; Petersen V; Schulze M; Seraphin J; Hoeffkes HG; Valdix AR; Schroeder J; Herrenberger J; Boxberger F; Leutgeb B; Hinke A; Kutscheidt A; Arnold D
    Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
    Bennouna J; Sastre J; Arnold D; Österlund P; Greil R; Van Cutsem E; von Moos R; Viéitez JM; Bouché O; Borg C; Steffens CC; Alonso-Orduña V; Schlichting C; Reyes-Rivera I; Bendahmane B; André T; Kubicka S;
    Lancet Oncol; 2013 Jan; 14(1):29-37. PubMed ID: 23168366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.